Despite quarterly revenue totals that were nearly cut in half compared to the same period last year, Moderna still expects to ...

Reports third quarter revenue of $1.0 billion, GAAP net loss of $(0.2) billion and GAAP EPS of $(0.51) Narrows 2025 projected ...

Moderna Inc. shares rose after the company posted a narrower third-quarter loss than Wall Street expected, a sign that its ...

Moderna posts a smaller Q3 loss, trims 2025 sales forecast, cuts R&D costs, and boosts cash outlook as COVID vaccine demand ...

Moderna (($MRNA)) has held its Q3 earnings call. Read on for the main highlights of the call. During Moderna’s recent earnings call, the sentiment ...

Moderna is suing Pfizer and BioNTech for infringing patents central to Moderna's mRNA technology platform used to develop the COVID vaccine, the company said in a press release Friday. A widely ...

Q3 2025 Earnings Call Transcript November 6, 2025 Moderna, Inc. beats earnings expectations. Reported EPS is $-0.51282, ...

Australia's Victoria state on Wednesday unveiled plans to develop an onshore messenger-RNA (mRNA) vaccine manufacturing facility and launched three mass coronavirus immunisation centres to speed up ...

Moderna Inc (MRNA) navigates a challenging quarter with significant cost reductions and strategic partnerships, despite a decline in COVID vaccine demand.

A cutting-edge RNA research facility promised to New South Wales more than four years ago will open its doors by next summer, ...

CHICAGO -- Moderna announced interim results of its Covid-19 vaccine for children younger than 6 on Wednesday. The company said two 25-microgram doses of its Covid-19 vaccine for children ages 6 ...